Products
- Anti-Obesity Compound Library
- GPCR/G Protein-Targeted Compounds
- Immunology/Inflammation-Targeted Compounds
- JAK/STAT-Targeted Compounds
- MAPK-Targeted Compounds
- Membrane Transporter/Ion Channel-Targeted Compounds
- Metabolism-Targeted Compounds
- NF-κB-Targeted Compounds
- Microbiology/Virology-Targeted Compounds
- Neuronal Signaling-Targeted Compounds
- PI3K/Akt/mTOR-Targeted Compounds
- Oxidation-reduction-Targeted Compounds
- Proteases/Proteasome-Targeted Compounds
- Stem Cells/Wnt-Targeted Compounds
- Tyrosine Kinase/Adaptors-Targeted Compounds
- Ubiquitin-Targeted Compounds
Online Inquiry
Losmapimod
Cat. No.:
0225LY-0501
Appearance:
Solid
Purity:
≥99%
Identity:
Confirmed by NMR, HPLC, and LC-MS.
Size:
Add to basket
Product Overview
Description:
Losmapimod is a powerful, orally bioavailable p38 MAPK inhibitor with pKi values of 8.1 and 7.6 for the α and β isoforms, respectively.
Synonym:
GSK-AHAB; GW856553X; 585543-15-3; 6-[5-(Cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl]-N-(2,2-dimethylpropyl)pyridine-3-carboxamide; 6-(5-(Cyclopropylcarbamoyl)-3-fluoro-2-methylphenyl)-N-neopentylnicotinamide
CAS No.:
585543-15-3
Compound CID:
11552706
Formula:
C22H26FN3O2
Formula Weight:
383.46
Specification
Targets&IC50:
p38α: 8.1(pKi); p38β: 7.6(pKi)
Relative Density:
1.21 g/cm3
Stability:
3 years in powder form.
Storage:
Storage at -20°C.
Applications:
Losmapimod can be used in cardiovascular and inflammatory research, especially in studies concerning p38 MAPK pathway inhibition.
Library Information
Target:
p38 MAPK
Receptor:
p38α; p38β
Pathways:
MAPK
Plate Number:
AOCL-7
Plate Location:
e3
Empty Location:
a1-h1; a12-h12
Container:
96-well plate
Formulation:
10mM DMSO
DMSO Max Solubility:
18.33 mg/mL; 47.8 mM
Water Max Solubility:
<1 mg/mL (insoluble or slightly soluble)
Ethanol Max Solubility:
39 mg/mL; 101.71 mM
ALogP:
3.689
HBA_Count:
3
HBD_Count:
2
Rotatable Bond:
6
